Results 21 to 30 of about 58,085 (295)

Dipeptidyl Peptidase 4 Inhibitors Decrease the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis C Infection and Type 2 Diabetes Mellitus: A Nationwide Study in Taiwan

Frontiers in Public Health, 2021
Introduction: Dipeptidyl peptidase 4 inhibitors (DPP-4 inhibitors) are incretin-based oral antidiabetic drugs. Previous studies have shown an association between increased plasma activity of DPP-4 and chronic hepatitis C virus (HCV) infection. Dipeptidyl
Wei-Hao Hsu, Wei-Hao Hsu, Shu-Ping Sue, Shu-Ping Sue, Hsiu-Ling Liang, Hsiu-Ling Liang, Chin-Wei Tseng, Chin-Wei Tseng, Hsiu-Chu Lin, Hsiu-Chu Lin, Wei-Lun Wen, Wei-Lun Wen, Mei-Yueh Lee, Mei-Yueh Lee   +13 more
doaj   +1 more source

Comparison of Vildagliptin and Pioglitazone in Korean Patients with Type 2 Diabetes Inadequately Controlled with Metformin [PDF]

Diabetes & Metabolism Journal, 2016
BackgroundWe compared the efficacies of vildagliptin (50 mg twice daily) relative to pioglitazone (15 mg once daily) as an add-on treatment to metformin for reducing glycosylated hemoglobin (HbA1c) levels in Korean patients with type 2 diabetes ...
Jong Ho Kim, Sang Soo Kim, Hong Sun Baek, In Kyu Lee, Dong Jin Chung, Ho Sang Sohn, Hak Yeon Bae, Mi Kyung Kim, Jeong Hyun Park, Young Sik Choi, Young Il Kim, Jong Ryeal Hahm, Chang Won Lee, Sung Rae Jo, Mi Kyung Park, Kwang Jae Lee, In Joo Kim   +16 more
doaj   +1 more source

The effect of sitagliptin on hepatic ischemic reperfusion injury in rats

Medical Journal of Dr. D.Y. Patil Vidyapeeth, 2020
Background: Dipeptidyl peptidase-4 (DPP4, DPPIV, CD26, EC 3.4.14.5) was found out more than four decades ago as a serine protease that severs N-terminal dipeptides from peptide substrates. DPP-4 inhibitors have been used in many animal models of lung and
Song-Chol Mun, Hye-Sun Hong
doaj   +1 more source

SARS-CoV-2 and diabetes: A potential therapeutic effect of dipeptidyl peptidase 4 inhibitors in diabetic patients diagnosed with COVID-19

Metabolism Open, 2021
COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 and has become an urgent economic and health challenge. Dipeptidyl peptidase 4 (DPP4), also mentioned as a cluster of differentiation 26 (CD26) is a serine exopeptidase found in two ...
Zemene Demelash Kifle, Alem Endeshaw Woldeyohanin, Chilot Abiyu Demeke   +2 more
doaj   +1 more source

Effects of dipeptidyl peptidase‐4 inhibition in vivo: Dipeptidyl peptidase‐4 inhibitor/gut microbiome crosstalk suggests novel therapeutic options for diabetes management [PDF]

Journal of Diabetes Investigation
Takuma Yasuda, Norio Harada, Nobuya Inagaki   +2 more
doaj   +2 more sources

Comparing treatment intensification and clinical outcomes of metformin and dipeptidyl peptidase‐4 inhibitors in treatment‐naïve patients with type 2 diabetes in Japan

Journal of Diabetes Investigation, 2020
Japan's guidelines emphasize tailored therapy, but do not guide physicians on the use of a specific regimen in drug‐naive patients. The role of long‐term initial therapy could be important in key elements of diabetes treatment, such as continuation of ...
Takeshi Horii, Makiko Iwasawa, Jyunichi Shimizu, Koichiro Atsuda   +3 more
doaj   +1 more source

Dipeptidyl peptidase-4 inhibitor-related renal disease

Journal of Diabetes and its Complications, 2023
Dipeptidyl peptidase-4 (DPP-4) inhibitors are widely used to treat type 2 diabetes (T2D). Lowering blood glucose is expected also to reduce the progression of diabetic nephropathy. We experienced a patient with T2D who achieved good glycemic control with a DPP-4 inhibitor but experienced rapid deterioration of renal function.
Atsuhiko, Suenaga, Naoki, Sawa, Yuki, Oba, Daisuke, Ikuma, Akinari, Sekine, Eiko, Hasegawa, Hiroki, Mizuno, Tatsuya, Suwabe, Sara, Ikeda, Tetsuro, Tsujimoto, Kei, Kono, Yukako, Shintani-Domoto, Keiichi, Kinowaki, Kenichi, Ohashi, Motoaki, Miyazono, Yutaka, Yamaguchi, Yoshifumi, Ubara   +16 more
openaire   +2 more sources

Effects of vildagliptin on ventricular function in patients with type 2 diabetes mellitus and heart failure: a randomized placebo-controlled trial [PDF]

, 2017
Objectives: This study sought to examine the safety of the dipeptidyl peptidase-4 inhibitor, vildagliptin, in patients with heart failure and reduced ejection fraction.
Bolli, Geremia B., Kothny, Wolfgang, Kozlovski, Plamen, Krum, Henry, Lewsey, James D., Lukashevich, Valentina, McMurray, John J.V., Ponikowski, Piotr   +7 more
core   +2 more sources

Characteristics of subjects with type 2 diabetes enrolled in randomized controlled trials and non‐randomized controlled trials in Japan: A systematic review

Journal of Diabetes Investigation, 2023
Aims/Introduction This study aimed to understand the characteristics of type 2 diabetes subjects enrolled in randomized controlled trials (RCTs) and non‐RCTs according to therapeutic regimens through systematic literature review.
Takashi Kadowaki, Ayako Shoji, Yurie Taguchi   +2 more
doaj   +1 more source

Bullous pemphigoid associated with dipeptidyl peptidase‐4 inhibitor showing unfavorable outcomes despite immediate discontinuation of medication

Clinical Case Reports, 2020
We experienced two cases of dipeptidyl peptidase‐4 (DPP‐4) inhibitor‐associated bullous pemphigoid (BP) showing an unfavorable course despite its discontinuation.
Yasutake Shinohara, Toshie Iijima, Shintaro Sakurai, Teruo Jojima, Eriko Ohira, Shujiro Hayashi, Isao Usui, Ken Igawa, Yoshimasa Aso   +8 more
doaj   +1 more source